Navigation Links
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Date:7/30/2009

the end of the third quarter 2009.

Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with direct antivirals currently in development. In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease and polymerase inhibitors. Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, and protease and nucleoside polymerase inhibitors retain full activity against mutations conferring resistance to ANA598.

ANA598 has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) Anadys' expectation that dosing in the ANA598 Phase II study will commence in the next several weeks; (ii) the ability for patients in the ANA598 Phase II study to achieve undetecta
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
4. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical ... cell therapies, announced today that RepliCel,s CEO, David Hall ... Minneapolis, Minnesota on August 5 th ... RepliCel,s 18-month milestones including CE Mark for its RCI-02 dermal ... data from both RCT-01 (tendon) and RCS-01 (skin) clinical trials ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
Breaking Biology Technology:RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: ... its fourth quarter and fiscal year 2008 on December 11, 2008, ... at 4:45 p.m. ET Martek will conduct a conference call to ... to the call live via webcast by visiting Martek,s web site ...
... Early to Mid-2009 , , ... the proprietary products division of Par Pharmaceutical Companies, Inc. ... development partner, MonoSol Rx, reported the successful completion of ... of ondansetron. The ondansetron thin film product is being ...
... (BCI), a,biopharmaceutical company utilizing its platform technology to ... new neurons for the treatment of,central nervous system ... Thompson to its board of directors. Thompson is ... tenure at Eli Lilly and Co. where he,focused ...
Cached Biology Technology:Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 2BrainCells Inc. Appoints David E. Thompson to Its Board of Directors 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... COLUMBUS, Ohio Very few athletic trainers associated with ... were following best practice standards for managing asthma among ... athletes with asthma, the dangers of the condition can ... severe to be incapacitating, or deadly. The lead report ...
... and inanimate phenomena may have more in common than previously ... University engineer Adrian Bejan and Penn State biologist James Marden. ... theory that flow systems from animal locomotion to the ... and minimize imperfections. Flows evolve to reduce friction or other ...
... Conan Doyle,s account of an isolated community of dinosaurs that ... no less appeal now than it did when it was ... recreate the lost world of dinosaurs, but today the fiction ... suggests that dinosaur bones from the Ojo Alamo Sandstone in ...
Cached Biology News:Athletes with asthma need more help from their team trainers 2Unifying the animate and the inanimate designs of nature 2Evidence of the 'Lost World' -- did dinosaurs survive the end Cretaceous extinctions? 2